[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

149

1 years may be quite more dramatic than in the time
2 frames that we've looked at so far. In a control
3 trial, it might be.
4 The other thing that I think is important,
5 particularly when you're looking at early population,
6 as you said, there are variations in progression rate
7 that are true for those things. And that may be
8 controlled by HLA BR type, which there is some
9 unpublished data that's sitting around waiting to be
10 published that really ought to be public at this
11 point, that we can identify people who are going to
12 respond and progress a little more quickly than
13 others.
14 I think that's a very important thing to
15 consider. These vaccines may be very good for people
16 with the right HLA type and no good for people with
17 the wrong HLA type.
18 That's why I think the basic science and
19 imaunology are absolutely critical for a trial like
20 this, but I also think you can't do it on 14,000 or
21 30,000 people.
22 I think a very strong balance has got to
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
(202) 234- 4433 WASHINGTON, D.C. 20005 (202) 234- 4433